Cardiovascular Risk in Climacteric Women: When to Begin the Hormone Treatment?

Hormonal changes determine a greater vulnerability in the cardiovascular system and thus, when considering the cardiovascular health of a menopausal woman, personalized medicine is decidedly required to ensure she is an appropriate candidate for menopausal hormone therapy (MHT). Tailoring to the individual patient is important for establishing the optimal dose, the formulation, and the administration route, as well as for ascertaining the effects of MHT initiated prior to the onset of a cardiovascular disease (CVD), for assessing whether there is a special group of women whose risk for CVD may increase or diminish with the therapy, and for clarifying the differences among the research protocols according to the MHT administration route in relation to the cardiovascular system.